Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection (Q41419861)

30 September 2017

Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection (English)

1 reference

30 September 2017

0 references

Clostridium difficile

0 references

author name string

Raghu U Varier

1

1 reference

30 September 2017

Eman Biltaji

2

1 reference

30 September 2017

Kenneth J Smith

3

1 reference

30 September 2017

Mark S Roberts

4

1 reference

30 September 2017

M Kyle Jensen

5

1 reference

30 September 2017

Joanne LaFleur

6

1 reference

30 September 2017

Richard E Nelson

7

1 reference

30 September 2017

1 April 2015

1 reference

Infection Control and Hospital Epidemiology

30 September 2017

1 reference

30 September 2017

36

1 reference

30 September 2017

4

1 reference

30 September 2017

438-444

1 reference

Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.

30 September 2017

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

An overview of fecal microbiota transplantation: techniques, indications, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Fecal microbiota transplantation for recurrent C difficile infection: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Recurrent Clostridium difficile-associated colitis responding to cholestyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Treatment of recurrent Clostridium difficile infection: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Clostridium difficile surveillance trends, Saxony, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Health outcomes in economic evaluation: the QALY and utilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Discounting and decision making in the economic evaluation of health-care technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Is fidaxomicin worth the cost? An economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Complications of colonoscopy: magnitude and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

The potential economic value of screening hospital admissions for Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Fecal microbiota transplantation: techniques, applications, and issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Treating Clostridium difficile infection with fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Fecal microbiota transplantation in relapsing Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

Operative strategies for diverticular peritonitis: a decision analysis between primary resection and anastomosis versus Hartmann's procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

7 January 2021

Tempered enthusiasm for fecal transplant

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

7 January 2021

Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency.

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

7 January 2021

Recurrent Clostridium difficile disease: epidemiology and clinical characteristics

1 reference

https://api.crossref.org/works/10.1017%2FICE.2014.80

7 January 2021

Identifiers

DOI

10.1017/ICE.2014.80

1 reference

30 September 2017

1 reference